CD8A and infection: Indeed, the earliest studies investigating the effectiveness of adoptive T cell transfer therapy revealed that patients receiving ex vivo expanded CMV specific CD8+ T cells are protected from both primary and reactivating infection (Riddell et al., 1992; Walter et al., 1995; Einsele et al., 2002; Peggs et al., 2003).